Disciplined Growth Investors Inc. MN Has $90.51 Million Stock Position in Core Laboratories Inc. (NYSE:CLB)

Disciplined Growth Investors Inc. MN raised its position in Core Laboratories Inc. (NYSE:CLB - Free Report) by 446.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,460,720 shares of the oil and gas company's stock after buying an additional 3,644,963 shares during the quarter. Core Laboratories comprises about 1.7% of Disciplined Growth Investors Inc. MN's portfolio, making the stock its 22nd largest position. Disciplined Growth Investors Inc. MN owned about 9.51% of Core Laboratories worth $90,508,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ariel Investments LLC boosted its position in shares of Core Laboratories by 20.4% during the 1st quarter. Ariel Investments LLC now owns 10,825,657 shares of the oil and gas company's stock worth $184,902,000 after acquiring an additional 1,837,258 shares in the last quarter. Congress Asset Management Co. MA boosted its holdings in shares of Core Laboratories by 17.6% in the 1st quarter. Congress Asset Management Co. MA now owns 1,606,745 shares of the oil and gas company's stock valued at $27,443,000 after purchasing an additional 240,989 shares in the last quarter. Earnest Partners LLC increased its stake in shares of Core Laboratories by 6.3% in the 2nd quarter. Earnest Partners LLC now owns 3,286,438 shares of the oil and gas company's stock valued at $66,682,000 after purchasing an additional 195,756 shares during the last quarter. Gendell Jeffrey L raised its holdings in shares of Core Laboratories by 101.7% during the 1st quarter. Gendell Jeffrey L now owns 326,890 shares of the oil and gas company's stock worth $5,583,000 after buying an additional 164,797 shares in the last quarter. Finally, Confluence Investment Management LLC bought a new stake in shares of Core Laboratories during the 1st quarter worth $2,495,000. 97.81% of the stock is currently owned by institutional investors and hedge funds.

Core Laboratories Trading Up 2.4 %

NYSE CLB traded up $0.42 during trading hours on Friday, reaching $18.27. The company's stock had a trading volume of 295,332 shares, compared to its average volume of 444,399. The firm has a fifty day simple moving average of $19.65 and a 200-day simple moving average of $18.70. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.39 and a quick ratio of 1.68. Core Laboratories Inc. has a 52 week low of $13.82 and a 52 week high of $25.20. The stock has a market cap of $856.86 million, a P/E ratio of 20.76, a P/E/G ratio of 1.09 and a beta of 2.37.

Core Laboratories (NYSE:CLB - Get Free Report) last issued its quarterly earnings results on Wednesday, July 24th. The oil and gas company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.01. Core Laboratories had a net margin of 5.44% and a return on equity of 15.20%. The company had revenue of $130.58 million for the quarter, compared to analyst estimates of $132.85 million. During the same quarter in the previous year, the business earned $0.23 earnings per share. Core Laboratories's revenue was up 2.1% compared to the same quarter last year. Equities analysts forecast that Core Laboratories Inc. will post 0.8 earnings per share for the current fiscal year.

Core Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Monday, August 5th were paid a $0.01 dividend. The ex-dividend date was Monday, August 5th. This represents a $0.04 annualized dividend and a dividend yield of 0.22%. Core Laboratories's payout ratio is 4.55%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CLB. Stifel Nicolaus lifted their target price on Core Laboratories from $18.00 to $22.00 and gave the company a "hold" rating in a research report on Friday, July 26th. StockNews.com lowered shares of Core Laboratories from a "hold" rating to a "sell" rating in a report on Tuesday, September 17th. Bank of America dropped their price objective on shares of Core Laboratories from $16.00 to $15.00 and set an "underperform" rating for the company in a research note on Monday, July 15th. Finally, Piper Sandler decreased their target price on shares of Core Laboratories from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Monday, July 15th. Two investment analysts have rated the stock with a sell rating and two have given a hold rating to the company's stock. Based on data from MarketBeat.com, Core Laboratories currently has a consensus rating of "Hold" and a consensus price target of $18.00.

Core Laboratories Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.